|
Novartis ends Tekturna trial on safety concerns
FiercePharma The drug company has decided to end a trial evaluating the med in Type 2 diabetes patients with renal impairment who are also at high risk of cardiovascular and renal events after researchers saw an increased number of adverse events–including … Novartis announces termination of ALTITUDE study with Rasilez®/ Tekturna® in … Novartis Terminates Combination Therapies, Studies With Rasilez/Tekturna Novartis Stops Key Trial Of Potential Blockbuster |
29
Jan 2010
I have type 2 diabetes, so I do know a little about this topic? Does it have any relevance?